| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/06/2008 | EP1951692A1 Oxazole and thiazole ppar modulator |
| 08/06/2008 | EP1951690A1 Heterocyclic cetp inhibitors |
| 08/06/2008 | EP1951689A1 P2x7 receptor antagonists and methods of use |
| 08/06/2008 | EP1951688A1 A novel compound, useful for pancreatic lipase inhibition and the process for isolation thereof |
| 08/06/2008 | EP1951687A1 N-hydroxyamide derivatives and use thereof |
| 08/06/2008 | EP1951686A1 Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof |
| 08/06/2008 | EP1951685A1 Novel quinazoline derivatives and their medical use |
| 08/06/2008 | EP1951684A1 Bi-aryl meta-pyrimidine inhibitors of kinases |
| 08/06/2008 | EP1951683A1 Pyrimidine derivatives for the treatment of cancer |
| 08/06/2008 | EP1951682A1 Novel 2-aminopyrimidinone or 2-aminopyridinone derivatives and their use |
| 08/06/2008 | EP1951681A1 Novel 2-aminopyrimidine derivatives and their use |
| 08/06/2008 | EP1951680A1 Novel 2-aminopyrimidinone derivatives and their use |
| 08/06/2008 | EP1951679A1 Imidazole compounds that modulate hsp90 activity |
| 08/06/2008 | EP1951678A1 Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
| 08/06/2008 | EP1951676A2 Lxr modulators |
| 08/06/2008 | EP1951674A1 Sulfonamide derivatives and use thereof for the modulation of metalloproteinases |
| 08/06/2008 | EP1951673A2 Heterocyclic cetp inhibitors |
| 08/06/2008 | EP1951672A1 Potassium channel inhibitors |
| 08/06/2008 | EP1951671A2 New pleuromutilin derivative and its use |
| 08/06/2008 | EP1951669A1 Acyl indoles, compositions containing such compounds and methods of use |
| 08/06/2008 | EP1951667A2 Thrombopoietin activity modulating compounds and methods |
| 08/06/2008 | EP1951665A1 Novel inhibitors of the lfa-1/icam-1 interaction, and uses thereof |
| 08/06/2008 | EP1951663A2 (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
| 08/06/2008 | EP1951660A1 Histamine-3 receptor antagonists |
| 08/06/2008 | EP1951659A2 Glucagon receptor antagonists, preparation and therapeutic uses |
| 08/06/2008 | EP1951658A1 Glucagon receptor antagonists, preparation and therapeutic uses |
| 08/06/2008 | EP1951656A1 Histone deacetylase inhibitors as therapeutics for neurological diseases |
| 08/06/2008 | EP1951655A2 Amino acid derivatives |
| 08/06/2008 | EP1951653A1 Salicylic acid derivatives |
| 08/06/2008 | EP1951643A1 Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity |
| 08/06/2008 | EP1951374A1 Treatment of sub-gingival pocket infections |
| 08/06/2008 | EP1951318A1 Inhibition of autophagy genes in cancer chemotherapy |
| 08/06/2008 | EP1951315A2 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| 08/06/2008 | EP1951312A1 Compounds |
| 08/06/2008 | EP1951309A2 Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
| 08/06/2008 | EP1951308A1 Combination preparations containing physiological cell membrane constituents including phosphatidylserine, choline and a pyrimidine nucleoside/nucleotide |
| 08/06/2008 | EP1951307A2 Combination of a cdk-inhibitor and a hdac-inhibitor |
| 08/06/2008 | EP1951304A1 Method for treating joint damage |
| 08/06/2008 | EP1951303A2 Therapy with cd4 binding peptides and radiation |
| 08/06/2008 | EP1951286A1 Combined use of dpp iv inhibitors and gastrin compounds |
| 08/06/2008 | EP1951274A1 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer |
| 08/06/2008 | EP1951266A2 Method for removing phosphate and polymer used therefore |
| 08/06/2008 | EP1951265A2 Compositions for the treatment of osteoarthritis and to nourish the synovial fluid |
| 08/06/2008 | EP1951264A2 Use of cicletanine and other furopyridines for treatment of hypertension |
| 08/06/2008 | EP1951262A2 Methods of using small molecule compounds for neuroprotection |
| 08/06/2008 | EP1951261A2 Compositions and methods for treating inflammatory disorders |
| 08/06/2008 | EP1951260A2 Functionalized phenolic compounds and absorbable therefrom |
| 08/06/2008 | EP1951259A1 Promoting wound healing by administering a prostaglandin e and granulocyte-macrophage colony stimulating factor |
| 08/06/2008 | EP1951258A2 Liquid formulations |
| 08/06/2008 | EP1951257A2 Crystalline forms |
| 08/06/2008 | EP1951256A1 Quetiapine in a controlled release formulation |
| 08/06/2008 | EP1951255A1 Staurosporine derivatives for use in alveolar rhabdomyosarcoma |
| 08/06/2008 | EP1951254A2 [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| 08/06/2008 | EP1951253A2 Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| 08/06/2008 | EP1951252A2 Tyrosine kinase inhibitors |
| 08/06/2008 | EP1951251A2 Spirohydantoin aryl cgrp receptor antagonists |
| 08/06/2008 | EP1951250A2 Chemical compounds |
| 08/06/2008 | EP1951249A2 Tyrosine kinase inhibitors |
| 08/06/2008 | EP1951247A2 Methods of treating nervous disorders |
| 08/06/2008 | EP1951246A2 Method of preventing oral staining |
| 08/06/2008 | EP1951245A2 Pharmaceutical compositions comprising methotrexate |
| 08/06/2008 | EP1951244A2 Calcilytic compounds |
| 08/06/2008 | EP1951243A2 Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor |
| 08/06/2008 | EP1951242A2 Combination therapy for the treatment of cancer |
| 08/06/2008 | EP1951241A2 Sigma ligands for neuronal regeneration and functional recovery |
| 08/06/2008 | EP1951240A2 Pharmaceutical compositions comprising buprenorphine |
| 08/06/2008 | EP1951239A2 Fixed ratio drug combination treatments for solid tumors |
| 08/06/2008 | EP1951238A2 Method for treating chronic pain |
| 08/06/2008 | EP1951236A2 Treatment of ophthalmic diseases with beta-amino alcohols |
| 08/06/2008 | EP1951235A2 Novel crystal forms of irinotecan hydrochloride |
| 08/06/2008 | EP1951234A2 Method of inhibiting flt3 kinase |
| 08/06/2008 | EP1951233A1 Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf) |
| 08/06/2008 | EP1951231A2 Camptothecin derivatives as chemoradiosensitizing agents |
| 08/06/2008 | EP1951230A2 Methods of treating or preventing cancer using pyridine carboxaldehyde pyridine thiosemicarbazone radiosensitizing agents |
| 08/06/2008 | EP1951229A2 Succinimide derivatives as ocular hypotensive agents |
| 08/06/2008 | EP1951228A2 Bicyclic spirohydantoin cgrp receptor antagonists |
| 08/06/2008 | EP1951227A2 Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure |
| 08/06/2008 | EP1951226A2 Methods of sensitizing cancer to therapy-induced cytotoxicity |
| 08/06/2008 | EP1951225A2 3-acylindole derivatives the preparation and the therapeutic use thereof |
| 08/06/2008 | EP1951224A2 Methods for treating disorders associated with hyperlipidemia in a mammal |
| 08/06/2008 | EP1951222A2 Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor |
| 08/06/2008 | EP1951221A1 Use of angeloyl-substituted ingenanes in combination with other agents to treat cancer |
| 08/06/2008 | EP1951220A2 Compositions for lowering serum cholesterol and/or triglycerides |
| 08/06/2008 | EP1951219A1 Wound-healing pharmaceutical compositions in the form of a cream based on amino acids and sodium hyaluronate |
| 08/06/2008 | EP1951218A1 Medicament for use in connection with cartilage impairment |
| 08/06/2008 | EP1951217A2 Chemical compounds |
| 08/06/2008 | EP1951216A2 Chemical compounds |
| 08/06/2008 | EP1951215A2 Hydrazone derivatives and uses thereof |
| 08/06/2008 | EP1951214A2 Modulation of osteoclast differentiation |
| 08/06/2008 | EP1951213A1 Use of alpha-hydroxy carbonyl compounds as reducing agents |
| 08/06/2008 | EP1951212A2 Compositions and methods for increasing insulin sensitivity |
| 08/06/2008 | EP1951211A1 Transdermal preparations containing hydrophobic non-steroidal anti-inflammatory drugs |
| 08/06/2008 | EP1951209A2 Multi-layered coating technology for taste masking |
| 08/06/2008 | EP1951208A2 Lipophilic vehicle-based dual controlled release matrix system as capsule fill |
| 08/06/2008 | EP1951207A2 Pharmaceutical composition |
| 08/06/2008 | EP1951206A1 Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| 08/06/2008 | EP1951205A2 Stable composition for a pharmaceutical formulation containing olanzapine |
| 08/06/2008 | EP1951204A2 Chemical preconditioning as a preventative or treatment for excitotoxic synaptic damage |
| 08/06/2008 | EP1951203A1 Intraorally rapidly disintegrating tablet |
| 08/06/2008 | EP1951200A2 Nanoemulsion compositions having anti-inflammatory activity |